Hyong Un

Relationship Between Buprenorphine Adherence and Health Service Utilization and Costs Among Opioid Dependent Patients

Buprenorphine-medication assisted therapy (B-MAT) is an effective treatment for opioid dependence, but may be considered cost-prohibitive based on ingredient cost alone. The purpose of this study was to use medical and pharmacy claims data to estimate the healthcare service utilization and costs associated with B-MAT adherence among a sample of opioid dependent members. Members were placed into two adherence groups based on 1-year medication possession ratio (≥ 0.80 vs. <0.80). The B-MAT adherent group incurred significantly higher pharmacy charges (adjusted means;

Primary care and behavioral health practice size: the challenge for health care reform.

6,156 vs.

Randomized controlled trial of a health plan-level mood disorders psychosocial intervention for solo or small practices

3,581), but lower outpatient (

Claims-based proxies of patient instability among commercially insured adults with schizophrenia

9,288 vs.

The Effects of Federal Parity on Substance Use Disorder Treatment

14,570), inpatient (

SYSTEM AND METHOD FOR PREDICTIVE MODELING DRIVEN BEHAVIORAL HEALTH CARE MANAGEMENT

10,982 vs.

Opioid analgesic-treated chronic pain patients at risk for problematic use.

26,470), ER (

Heterogeneity of Nonadherent Buprenorphine Patients: Subgroup Characteristics and Outcomes

1,891 vs.

Relapse In Opioid Use Disorder: Implications For Health Care Utilization And Costs

4,439), and total healthcare charges (

The Association Between Buprenorphine Medication-Assisted Treatment Adherence And Health Care Service Utilization And Costs

28,458 vs.